1. 1. Nishimura RA, Vahanian A, Eleid MF, Mack MJ. Mitral valve disease - current management and future challenges. Lancet 2016;387:1324-34. https://doi.org/10.1016/S0140-6736(16)00558-4; PMID: 27025438.
2. 2. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252-89. https://doi.org/10.1016/j.jacc.2017.03.011; PMID: 28315732.
3. 3. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-91. https://doi.org/10.1093/eurheartj/ehx391; PMID: 28886619.
4. 4. Stone GW, Vahanian AS, Adams DH, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: a consensus document from the Mitral Valve Academic Research Consortium. J Am Coll Cardiol 2015;66:278-307. https://doi.org/10.1016/j.jacc.2015.05.046; PMID: 26184622.
5. 5. Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol 2008;52:319-26. https://doi.org/10.1016/j.jacc.2008.02.084; PMID: 18652937.